リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

大学・研究所にある論文を検索できる 「The impact of chronic Epstein–Barr virus infection on the liver graft of pediatric liver transplant recipients: A retrospective observational study」の論文概要。リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。
リケラボ

コピーが完了しました

URLをコピーしました

論文の公開元へ論文の公開元へ
書き出し

The impact of chronic Epstein–Barr virus infection on the liver graft of pediatric liver transplant recipients: A retrospective observational study

Shizuku, Masato Kamei, Hideya Yoshizawa, Atsushi Ito, Yoshinori Ogura, Yasuhiro Yoshikawa, Junichi Kurata, Nobuhiko Jobara, Kanta Kodera, Yasuhiro 名古屋大学

2021.10

概要

Background:
Chronic high Epstein–Barr virus loads (CHEBV) are commonly observed in pediatric liver transplant patients. However, it is unclear how CHEBV impacts the liver graft. The aim of this study was to clarify the clinical and pathological impacts of CHEBV on the liver graft.

Methods
From 2012 through 2020, we retrospectively investigated 46 pediatric liver transplant patients (under 16 years old) who survived ≥ 6 months. The patients were divided into two groups: CHEBV group (EBV DNA >10,000 IU/mL of whole blood for ≥ 6 months) and NCHEBV group (patients who did not meet CHEBV criteria). Tacrolimus was reduced to < 3.0 ng/mL in patients with EBV DNA > 5,000 IU/mL. Blood biochemistry date and pathological findings, obtained at the time of protocol and episodic biopsy, were compared between the two groups.

Results
Out of 46 patients, 28 CHEBV and 18 NCHEBV patients were enrolled. The blood biochemical examination did not show a significant difference between the two groups. In addition, no significant differences between the two groups were found in the pathological findings, including frequency of late acute rejection and the progression of fibrosis at the time of both protocol and episodic biopsy. Appropriate adjustment of immunosuppression for CHEBV management may have contributed to the prevention of the progression of fibrosis.

Conclusion
CHEBV had little adverse effect on the liver graft. Graft fibrosis might have been avoided through optimal dose modification of tacrolimus. Further long-term monitoring is necessary because CHEBV may affect the pediatric liver graft in the long term.

論文の公開元へ

この論文で使われている画像

関連論文

関連論文をもっと見る

参考文献

1. Mynarek M, Schober T, Behrends U, Maecker-Kolhoff B. Posttransplant Lymphoproliferative Disease after Pediatric Solid Organ Transplantation. Clin Dev Immunol. 2013:14.

2. Cacciarelli TV, Reyes J, Jaffe R, et al. Primary tacrolimus (FK506) therapy and the long-term risk of post-transplant lymphoproliferative disease in pediatric liver transplant recipients. Pediatric Transplantation. 2001;5(5):359-364.

3. Green M, Michaels MG. Epstein-Barr Virus Infection and Posttransplant Lymphoproliferative Disorder. American Journal of Transplantation. 2013;13:41- 54.

4. Kullberg-Lindh C, Saalman R, Olausson M, Herlenius G, Lindh M. Epstein-Barr virus DNA monitoring in serum and whole blood in pediatric liver transplant recipients who do or do not discontinue immunosuppressive therapy. Pediatric Transplantation. 2017;21(5).

5. Kamei H, Ito Y, Kawada J, et al. Risk factors and long-term outcomes of pediatric liver transplant recipients with chronic high Epstein-Barr virus loads. Transplant Infectious Disease. 2018;20(4).

6. Seo E, Kim J, Oh SH, Kim KM, Kim DY, Lee J. Epstein-Barr viral load monitoring for diagnosing post-transplant lymphoproliferative disorder in pediatric liver transplant recipients. Pediatric Transplantation. 2020;24(4):10.

7. Kullberg-Lindh C, Ascher H, Saalman R, Olausson M, Lindh M. Epstein-Barr viremia levels after pediatric liver transplantation as measured by real-time polymerase chain reaction. Pediatric Transplantation. 2006;10(1):83-89.

8. Chen HS, Ho MC, Hu RH, et al. Roles of Epstein-Barr virus viral load monitoring in the prediction of posttransplant lymphoproliferative disorder in pediatric liver transplantation. J Formos Med Assoc. 2019;118(9):1362-1368.

9. Bingler MA, Feingold B, Miller SA, et al. Chronic high Epstein-Barr viral load state and risk for late-onset posttransplant lymphoproliferative disease/lymphoma in children. American Journal of Transplantation. 2008;8(2):442-445.

10. Ganschow R, Schulz T, Meyer S, Broering TC, Burdelski M. Low-dose immunosuppression reduces the incidence of post-transplant lymphoproliferative disease in pediatric liver graft recipients. Journal of Pediatric Gastroenterology and Nutrition. 2004;38(2):198-203.

11. Narkewicz MR, Green M, Dunn S, et al. Decreasing Incidence of Symptomatic Epstein-Barr Virus Disease and Posttransplant Lymphoproliferative Disorder in Pediatric Liver Transplant Recipients: Report of the Studies of Pediatric Liver Transplantation Experience. Liver Transplantation. 2013;19(7):730-740.

12. Koshiba T, Li Y, Takemura M, et al. Clinical, immunological, and pathological aspects of operational tolerance after pediatric living-donor liver transplantation. Transplant Immunology. 2007;17(2):94-97.

13. Orii T, Ohkohchi N, Satomi S, Hoshino Y, Kimura H. Decreasing the Epstein-Barr virus load by adjusting the FK506 blood level. Transplant International. 2002;15(11):529-534.

14. Ito Y, Suzuki M, Kawada J, Kimura H. Diagnostic values for the viral load in peripheral blood mononuclear cells of patients with chronic active Epstein-Barr virus disease. J Infect Chemother. 2016;22(4):268-271.

15. Bakker NA, van Imhoff GW, Verschuuren EAM, van Son WJ. Presentation and early detection of post-transplant lymphoproliferative disorder after solid organ transplantation. Transplant International. 2007;20(3):207-218.

16. Nacif LS, Pinheiro RS, Pecora RAD, et al. LATE ACUTE REJECTION IN LIVER TRANSPLANT: A SYSTEMATIC REVIEW. ABCD-Arq Bras Cir Dig-Braz Arch Dig Surg. 2015;28(3):212-215.

17. Bedossa P, Bioulacsage P, Callard P, et al. INTRAOBSERVER AND INTEROBSERVER VARIATIONS IN LIVER-BIOPSY INTERPRETATION IN PATIENTS WITH CHRONIC HEPATITIS-C. Hepatology. 1994;20(1):15-20.

18. Kanda Y. Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplantation. 2013;48(3):452-458.

19. Webber SA, Naftel DC, Fricker FJ, et al. Lymphoproliferative disorders after paediatric heart transplantation: a multi-institutional study. Lancet. 2006;367(9506):233-239.

20. Green M, Michaels MG, Katz BZ, et al. CMV-IVIG for prevention of Epstein Barr virus disease and posttransplant lymphoproliferative disease in pediatric liver transplant recipients. American Journal of Transplantation. 2006;6(8):1906-1912.

21. Woo YS, Lee KH, Lee KT, et al. Postoperative changes of liver enzymes can distinguish between biliary stricture and graft rejection after living donor liver transplantation A longitudinal study. Medicine. 2017;96(40):7.

22. Wiesner RH, Demetris AJ, Belle SH, et al. Acute hepatic allograft rejection: Incidence, risk factors, and impact on outcome. Hepatology. 1998;28(3):638-645.

23. Yoshitomi M, Koshiba T, Haga H, et al. Requirement of Protocol Biopsy Before and After Complete Cessation of Immunosuppression After Liver Transplantation. Transplantation. 2009;87(4):606-614.

参考文献をもっと見る

全国の大学の
卒論・修論・学位論文
を
一発検索！

この論文の関連論文を見る